MX2018012902A - Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. - Google Patents
Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.Info
- Publication number
- MX2018012902A MX2018012902A MX2018012902A MX2018012902A MX2018012902A MX 2018012902 A MX2018012902 A MX 2018012902A MX 2018012902 A MX2018012902 A MX 2018012902A MX 2018012902 A MX2018012902 A MX 2018012902A MX 2018012902 A MX2018012902 A MX 2018012902A
- Authority
- MX
- Mexico
- Prior art keywords
- lysosomal
- disorders
- methods
- compositions
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Abstract
La presente invención se refiere a composiciones y métodos para tratar enfermedades de almacenamiento lisosomal y métodos para usar trehalosa.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662325535P | 2016-04-21 | 2016-04-21 | |
US201762475295P | 2017-03-23 | 2017-03-23 | |
PCT/US2017/028904 WO2017185010A1 (en) | 2016-04-21 | 2017-04-21 | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018012902A true MX2018012902A (es) | 2019-06-06 |
Family
ID=60089338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018012902A MX2018012902A (es) | 2016-04-21 | 2017-04-21 | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. |
Country Status (11)
Country | Link |
---|---|
US (3) | US10512656B2 (es) |
EP (1) | EP3445451B1 (es) |
JP (1) | JP7302871B2 (es) |
CN (1) | CN109789316B (es) |
AU (1) | AU2017252563B2 (es) |
BR (1) | BR112018071684A2 (es) |
CA (1) | CA3021846A1 (es) |
DK (1) | DK3445451T3 (es) |
MX (1) | MX2018012902A (es) |
NZ (1) | NZ748599A (es) |
WO (1) | WO2017185010A1 (es) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3021846A1 (en) | 2016-04-21 | 2017-10-26 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
CN113164414A (zh) * | 2018-10-24 | 2021-07-23 | 纳维托制药有限公司 | 多晶型化合物和其用途 |
CA3136360A1 (en) * | 2019-04-12 | 2020-10-15 | Loma Linda University | Methods for treatment of niemann-pick disease type c |
EP4028025A4 (en) * | 2019-09-09 | 2023-07-19 | University of Pittsburgh - of the Commonwealth System of Higher Education | METHODS OF RESTORING LYSOSOMAL FUNCTION OF RETINAL PIGMENT EPITHELIAL CELLS BY TFEB ACTIVATION |
US20220387463A1 (en) * | 2019-10-01 | 2022-12-08 | Seelos Therapeutics, Inc. | Trehalose formulations and uses thereof |
EP3944858A1 (en) | 2020-07-30 | 2022-02-02 | Beyond Batten Disease Foundation | Combination product containing trehalose and miglustat for treating lysosomal diseases |
KR102580852B1 (ko) * | 2021-04-13 | 2023-09-20 | 강원대학교 산학협력단 | 발리다마이신 a를 포함하는 뇌전증 완화 및 치료용 조성물 |
WO2023141606A2 (en) * | 2022-01-20 | 2023-07-27 | The Johns Hopkins University | Lysosomal dysfunction in neurological and psychiatric disorders |
TW202400160A (zh) * | 2022-04-22 | 2024-01-01 | 美商米突倍基公司 | 轉錄因子eb活化子及其用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69529026T2 (de) * | 1994-07-19 | 2003-07-17 | Hayashibara Biochem Lab | Trehalose, ihre Herstellung und ihre Verwendung |
EP2932982B1 (en) | 2005-05-17 | 2018-10-03 | Amicus Therapeutics, Inc. | A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
EP3679942A1 (en) * | 2009-06-17 | 2020-07-15 | BioMarin Pharmaceutical Inc. | Formulations for lysosomal enzymes |
US20130312784A1 (en) | 2012-05-24 | 2013-11-28 | For Your Ease Only, Inc. | Cosmetic organizer |
US9750712B2 (en) * | 2012-12-07 | 2017-09-05 | Rush University Medical Center | Composition and method for treating neuronal ceroid lipofuscinosis |
MX2015008837A (es) | 2013-01-09 | 2015-10-14 | Amicus Therapeutics Inc | Composiciones parenterales estables de dnj. |
AU2014264228A1 (en) | 2013-05-07 | 2015-11-12 | Bio Blast Pharma Ltd. | Treatment of protein aggregation myopathic and neurodegenerative diseases by parenteral administration of trehalose |
US9084720B2 (en) | 2013-05-07 | 2015-07-21 | BioBlast Pharma Ltd. | Compositions and methods for treating oculopharyngeal muscular dystrophy |
JP6130224B2 (ja) * | 2013-05-27 | 2017-05-17 | 公益財団法人微生物化学研究会 | 新規化合物レンツトレハロース、その製造方法、及びその用途、並びに、新規微生物 |
WO2014200705A1 (en) * | 2013-06-14 | 2014-12-18 | Stc.Unm | Treatment of autophagy-related disorders |
US9927437B2 (en) | 2013-12-12 | 2018-03-27 | The Brigham And Women's Hospital, Inc. | Treating neurodegenerative disease |
EP3086784B9 (en) * | 2013-12-23 | 2019-10-16 | BCN Peptides, S.A. | Bicalutamide analogs or (s)-bicalutamide as exocytosis activating compounds for use in the treatment of a lysosomal storage disorder or glycogenosis |
EP3413898A4 (en) * | 2016-02-08 | 2019-09-25 | Junaxo, Inc. | USE OF TREHALOSIS FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
CA3021846A1 (en) | 2016-04-21 | 2017-10-26 | Baylor College Of Medicine | Compositions and methods for the treatment of lysosomal storage disorders and disorders characterized by lysosomal dysfunction |
EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
-
2017
- 2017-04-21 CA CA3021846A patent/CA3021846A1/en active Pending
- 2017-04-21 BR BR112018071684-7A patent/BR112018071684A2/pt active Search and Examination
- 2017-04-21 AU AU2017252563A patent/AU2017252563B2/en active Active
- 2017-04-21 EP EP17786739.7A patent/EP3445451B1/en active Active
- 2017-04-21 CN CN201780038419.8A patent/CN109789316B/zh active Active
- 2017-04-21 JP JP2019531851A patent/JP7302871B2/ja active Active
- 2017-04-21 MX MX2018012902A patent/MX2018012902A/es unknown
- 2017-04-21 WO PCT/US2017/028904 patent/WO2017185010A1/en active Application Filing
- 2017-04-21 DK DK17786739.7T patent/DK3445451T3/da active
- 2017-04-21 NZ NZ748599A patent/NZ748599A/en unknown
- 2017-04-21 US US15/494,136 patent/US10512656B2/en active Active
-
2019
- 2019-04-04 US US16/375,521 patent/US20200000832A1/en not_active Abandoned
- 2019-04-04 US US16/375,445 patent/US11083741B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11083741B2 (en) | 2021-08-10 |
JP2021517552A (ja) | 2021-07-26 |
EP3445451A4 (en) | 2019-12-18 |
US10512656B2 (en) | 2019-12-24 |
EP3445451B1 (en) | 2021-08-18 |
EP3445451A1 (en) | 2019-02-27 |
CN109789316A (zh) | 2019-05-21 |
US20200000832A1 (en) | 2020-01-02 |
WO2017185010A1 (en) | 2017-10-26 |
DK3445451T3 (da) | 2021-11-08 |
CN109789316B (zh) | 2022-09-27 |
CA3021846A1 (en) | 2017-10-26 |
US20170304339A1 (en) | 2017-10-26 |
NZ748599A (en) | 2022-08-26 |
JP7302871B2 (ja) | 2023-07-04 |
BR112018071684A2 (pt) | 2019-02-19 |
AU2017252563A1 (en) | 2018-12-06 |
US20190321383A1 (en) | 2019-10-24 |
AU2017252563B2 (en) | 2022-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018012902A (es) | Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal. | |
GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
PH12016501600A1 (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
PH12019500494A1 (en) | Formulations of (r)-2-amino-3-phenylpropyl carbamate | |
GB2541571A (en) | Pharmaceutical compositions | |
TN2017000134A1 (en) | 2-amino-3,5-difluoro-3,6-dimethyl-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors for treating alzheimer's disease | |
PH12017500841B1 (en) | 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors | |
MX2020005567A (es) | Metodos de tratamiento con asparaginasa. | |
PH12018501279A1 (en) | Compositions comprising 15-hepe and methods of using the same | |
PH12020550023A1 (en) | Compositions for treating stress-related disorders | |
ZA202002066B (en) | Compositions and methods for the treatment of eye disorders | |
PH12017501028A1 (en) | Treatment of retinal degeneration using progenitor cells | |
MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. | |
IL264070A (en) | Methods and preparations for the treatment of disorders and diseases involving rdh12 | |
MX2020009966A (es) | Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina. | |
MX2017004819A (es) | Metodos de tratamiento de transtornos urológicos usando sarm. | |
MX2019004804A (es) | Tratamiento para el prurigo nodula. | |
MX2018009662A (es) | Metodo y composicion farmaceutica para tratamiento de neurodegeneracion. | |
GEP201706795B (en) | Hexahydrofuropyrroles as pde1 inhibitors | |
PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases | |
HK1258884A1 (zh) | 用於治療竇疾病和病症的組合物和方法 | |
EA201592012A1 (ru) | Применение флагеллина для улучшенной химиотерапии | |
MA39718A (fr) | Compositions et méthodes d'utilisation de celles-ci | |
EA201492019A1 (ru) | Способы лечения рака с помощью липопептидов |